1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Emyria Limited
  6. News
  7. Summary
    EMD   AU0000073645

EMYRIA LIMITED

(EMD)
  Report
Delayed Australian Stock Exchange  -  05/16 02:11:03 am EDT
0.2850 AUD   +5.56%
05/09Emyria Limited Receives Further Positive MDMA Analogue Screening Results
CI
04/26EMYRIA : Appendix 4C - Quarterly
PU
04/14Emyria to Complete Dosing for Phase 1 Cannabidiol Trial
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Emyria to Start Phase 1 Clinical Trial for Ultra-Pure Cannabidiol Capsule; Shares Climb 3%

01/19/2022 | 09:50pm EDT


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AURORA CANNABIS INC. 15.87% 3.65 Delayed Quote.-46.72%
AUXLY CANNABIS GROUP INC. 17.24% 0.17 Delayed Quote.-8.11%
CANOPY GROWTH CORPORATION 9.17% 7.62 Delayed Quote.-30.98%
CRONOS GROUP INC. 6.23% 4.26 Delayed Quote.-14.46%
EMYRIA LIMITED 5.56% 0.285 Delayed Quote.-29.87%
HEXO CORP. 0.00% 0.35 Delayed Quote.-60.23%
ORGANIGRAM HOLDINGS INC. 4.61% 1.59 Delayed Quote.-28.38%
THE GREEN ORGANIC DUTCHMAN HOLDINGS LTD. 5.26% 0.1 Delayed Quote.5.26%
All news about EMYRIA LIMITED
05/09Emyria Limited Receives Further Positive MDMA Analogue Screening Results
CI
04/26EMYRIA : Appendix 4C - Quarterly
PU
04/14Emyria to Complete Dosing for Phase 1 Cannabidiol Trial
MT
04/13Emyria Limited Announces EMD-RX5 Dosing to Complete for Phase 1 Clinical Trial
CI
04/12Emyria Hires Contract Research Organization for Upcoming Phase 3 Cannabidiol Trial
MT
04/07Emyria Begins Dosing Patients for Phase 1 Clinical Trial for Cannabidiol Drug
MT
04/06Emyria Limited Commences Dosing for EMD-RX5 Phase 1 Human Clinical Trial
CI
03/24EMYRIA : Broker Briefing Presentation
PU
03/18EMYRIA : Addendum to Notice of Meeting and Proxy Form
PU
03/17Emyria Launches Second Highly Bioavailable Cannabidiol Capsule
MT
More news
Financials
Sales 2021 1,98 M 1,37 M 1,37 M
Net income 2021 -4,91 M -3,39 M -3,39 M
Net cash 2021 5,58 M 3,86 M 3,86 M
P/E ratio 2021 -8,24x
Yield 2021 -
Capitalization 74,3 M 51,4 M 51,4 M
EV / Sales 2020 5,68x
EV / Sales 2021 21,0x
Nbr of Employees -
Free-Float 44,3%
Chart EMYRIA LIMITED
Duration : Period :
Emyria Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EMYRIA LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Managers and Directors
Michael Winlo Chief Executive Officer, Director & MD
Su-Mei Sain Chief Financial Officer
Stewart James Washer Executive Chairman
Patrizia Washer Research Director
Margaret Somerville National Clinical Director